BayesRVAT enhances rare-variant association testing through Bayesian aggregation of functional annotations

  1. Francesco Paolo Casale1,4
  1. 1 Helmholtz Munich, Institute of AI for Health;
  2. 2 Chan Zuckerberg Initiative;
  3. 3 ETH Zurich, D-BSSE
  • * Corresponding author; email: fncpaolo.casale{at}gmail.com
  • Abstract

    Gene-level rare variant association tests (RVATs) are essential for uncovering disease mechanisms and identifying therapeutic targets. Advances in sequence-based machine learning have generated diverse variant pathogenicity scores, creating opportunities to improve RVATs. However, existing methods often rely on rigid models or single annotations, limiting their ability to leverage these advances. We introduce BayesRVAT, a Bayesian rare variant association test that jointly models multiple annotations. By specifying priors on annotation effects and estimating gene–trait-specific posterior burden scores, BayesRVAT flexibly captures diverse rare-variant architectures. In simulations, BayesRVAT improves power while maintaining calibration. In UK Biobank analyses, it detects 10.2% more blood-trait associations and reveals novel gene–disease links, including PRPH2 with retinal disease. Integrating BayesRVAT within omnibus frameworks further increases discoveries, demonstrating that flexible annotation modeling captures complementary signals beyond existing burden and variance-component tests.

    • Received March 24, 2025.
    • Accepted October 22, 2025.

    This manuscript is Open Access.

    This article, published in Genome Research, is available under a Creative Commons License (Attribution 4.0 International license), as described at http://creativecommons.org/licenses/by/4.0/.

    Articles citing this article

    OPEN ACCESS ARTICLE
    ACCEPTED MANUSCRIPT

    This Article

    1. Genome Res. gr.280689.125 Published by Cold Spring Harbor Laboratory Press

    Article Category

    ORCID

    Share

    Preprint Server